DE69934380D1 - Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung - Google Patents

Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung

Info

Publication number
DE69934380D1
DE69934380D1 DE69934380T DE69934380T DE69934380D1 DE 69934380 D1 DE69934380 D1 DE 69934380D1 DE 69934380 T DE69934380 T DE 69934380T DE 69934380 T DE69934380 T DE 69934380T DE 69934380 D1 DE69934380 D1 DE 69934380D1
Authority
DE
Germany
Prior art keywords
insulinotropic activity
administering peptides
peptides
administering
insulinotropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69934380T
Other languages
English (en)
Inventor
Benjamin Lee Hughes
Ronald Keith Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69934380(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69934380D1 publication Critical patent/DE69934380D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69934380T 1998-08-28 1999-08-25 Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung Expired - Lifetime DE69934380D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9827398P 1998-08-28 1998-08-28
US10001298P 1998-09-11 1998-09-11

Publications (1)

Publication Number Publication Date
DE69934380D1 true DE69934380D1 (de) 2007-01-25

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934380T Expired - Lifetime DE69934380D1 (de) 1998-08-28 1999-08-25 Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung

Country Status (21)

Country Link
EP (1) EP0997151B1 (de)
JP (1) JP2002523466A (de)
KR (1) KR20010073033A (de)
CN (1) CN1314818A (de)
AR (1) AR022368A1 (de)
AT (1) ATE347902T1 (de)
AU (1) AU764371B2 (de)
BR (1) BR9913284A (de)
CA (1) CA2341454A1 (de)
CO (1) CO5090908A1 (de)
CZ (1) CZ2001690A3 (de)
DE (1) DE69934380D1 (de)
EA (1) EA200100289A1 (de)
HR (1) HRP20010141A2 (de)
HU (1) HUP0103369A3 (de)
IL (1) IL141241A0 (de)
NO (1) NO20010982L (de)
PE (1) PE20001031A1 (de)
PL (1) PL346317A1 (de)
TR (1) TR200100600T2 (de)
WO (1) WO2000012116A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP1542712A2 (de) * 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1-formulierungen mit zeitverzögerter wirkung
IL160917A0 (en) 2001-10-18 2004-08-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
CA2493478C (en) * 2002-08-01 2014-11-18 Mannkind Corporation Cell transport compositions and uses thereof
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
CA2549582A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
BRPI0514293B1 (pt) 2004-08-23 2022-07-19 Mannkind Corporation Sistema microparticulado para distribuição de droga
KR100704447B1 (ko) * 2005-05-16 2007-04-09 정용현 3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
BRPI0616071B8 (pt) 2005-09-14 2021-05-25 Mannkind Corp métodos de revestir uma micropartícula cristalina pré-formada em suspensão com um agente ativo
LT1965823T (lt) * 2005-11-04 2016-10-10 Glaxosmithkline Llc Hipoglikeminių agentų skyrimo būdai
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
MX360812B (es) 2006-02-22 2018-11-16 Mannkind Corp Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo.
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2211842B1 (de) * 2007-10-24 2015-08-12 MannKind Corporation Eine inhalierbare, trockenpulver-formulierung, enthaltend glp-1 zur verwendung in der behandlung von hyperglykämie und diabetes durch pulmonale verabreichung
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (de) 2008-06-20 2021-12-29 MannKind Corporation Interaktives Gerät für die Echtzeit-Profilierung von Inhalationsversuchen
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2379100T3 (en) 2009-01-08 2014-12-01 Mannkind Corp Treatment of hyperglycemia with GLP-1
EP2405963B1 (de) 2009-03-11 2013-11-06 MannKind Corporation Gerät, system und verfahren zur messung von widerstand in einem inhaliergerät
CN102647979B (zh) 2009-06-12 2015-03-04 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
EP2496295A1 (de) 2009-11-03 2012-09-12 MannKind Corporation Vorrichtung und verfahren zur simulation von einatmungsanstrengungen
JP6385673B2 (ja) 2010-06-21 2018-09-05 マンカインド コーポレイション 乾燥粉末薬物送達システム
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
RU2650035C2 (ru) 2012-07-12 2018-04-06 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (de) 2013-03-15 2019-08-21 MannKind Corporation Mikrokristalline diketopiperazinzusammensetzungen und verfahren
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11359267B2 (en) 2017-02-21 2022-06-14 Jfe Steel Corporation High-carbon hot-rolled steel sheet and method for manufacturing the same
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
UA72181C2 (uk) * 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1019031A4 (de) * 1997-07-18 2003-02-05 Infimed Inc Biologisch abbaubare makromere zur kontrollierten abgabe biologisch aktiver substanzen

Also Published As

Publication number Publication date
CN1314818A (zh) 2001-09-26
EP0997151A3 (de) 2000-09-20
AR022368A1 (es) 2002-09-04
EA200100289A1 (ru) 2001-10-22
CA2341454A1 (en) 2000-03-09
NO20010982D0 (no) 2001-02-27
EP0997151B1 (de) 2006-12-13
ATE347902T1 (de) 2007-01-15
NO20010982L (no) 2001-04-27
IL141241A0 (en) 2002-03-10
PL346317A1 (en) 2002-01-28
KR20010073033A (ko) 2001-07-31
HUP0103369A2 (hu) 2002-02-28
BR9913284A (pt) 2001-05-15
TR200100600T2 (tr) 2001-07-23
AU764371B2 (en) 2003-08-14
WO2000012116A1 (en) 2000-03-09
JP2002523466A (ja) 2002-07-30
EP0997151A2 (de) 2000-05-03
PE20001031A1 (es) 2000-10-12
AU5584199A (en) 2000-03-21
HUP0103369A3 (en) 2002-03-28
CZ2001690A3 (cs) 2002-04-17
CO5090908A1 (es) 2001-10-30
HRP20010141A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE69934380D1 (de) Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung
DE69900746D1 (de) Gesteuerte verabreichung von peptiden oder proteinen
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
PL339463A1 (en) April - novel protein of growth promoting action
DE69831027D1 (de) Vorrichtungen zur Entnahme von weichem Gewebe
FI961819A (fi) Proteiini:farnesyylitransferaasin substituoidut di- ja tripeptidi-inhibiittorit
DE59911005D1 (de) Aminosäureester von arylsulfonamiden und analoga
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69826705D1 (de) Verfahren zur dermalen verabreichung von polypeptiden
DE69830660D1 (de) Behandlung von atemstillstand im schlaf
DE69405201D1 (de) Methode zur Reinigung von Lactid
DE69524748D1 (de) Methode zur Wirkungssteigerung von Agrarchemikalien
DE69824823D1 (de) Methode zur abgasbehandlung
DE69841311D1 (de) Prothese zur linderung von kiefergelenkproblemen
DK0964856T3 (da) Bicycliske aromatiske aminosyrer
DE69825625D1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
DE69815167D1 (de) Methode zur Bestimmung von Salz Stöchiometrie
DE69826951D1 (de) Verfahren zur Gewebepflege
DE60039773D1 (de) Chimäres pflanzenvirus mit peptiden von mucin
ATE230926T1 (de) Synergistische mischungen von ausgewählten aminosäuren
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69737067D1 (de) Vakzine zur behandlung von mycosen
PL332282A1 (en) Application of proteins as factors against autoimmunological diseases

Legal Events

Date Code Title Description
8332 No legal effect for de